Q4 25 EPS
$8.08
BEAT +5.65%
Est. $7.65
Q4 25 Revenue
$72.47B
BEAT +9.17%
Est. $66.38B
vs S&P Since Q4 25
-5.5%
TRAILING MARKET
CI +0.8% vs S&P +6.4%
Full Year 2025 Results
FY 25 EPS
$29.84
FY 25 Revenue
$274.90B
Market Reaction
Did CI Beat Earnings? Q4 2025 Results
The Cigna Group delivered a strong finish to fiscal 2025, posting fourth-quarter adjusted earnings of $8.08 per share against a Wall Street consensus of $7.65, a beat of 5.65%, while revenue of $72.47 billion topped estimates by 9.17% and grew 10.6% … Read more The Cigna Group delivered a strong finish to fiscal 2025, posting fourth-quarter adjusted earnings of $8.08 per share against a Wall Street consensus of $7.65, a beat of 5.65%, while revenue of $72.47 billion topped estimates by 9.17% and grew 10.6% year over year. The primary engine behind those results was Evernorth Health Services, whose specialty pharmacy business drove Q4 adjusted revenues 17% higher and powered the segment's full-year top-line growth of 16%, more than offsetting a 16% revenue decline in Cigna Healthcare tied to the March 2025 divestiture of its Medicare businesses to HCSC. Operational discipline was equally visible in the SG&A expense ratio, which tightened to 5.0% from 5.9% a year earlier. Looking ahead, management guided 2026 adjusted revenues to approximately $280.00 billion and adjusted earnings of at least $30.25 per share, signaling continued confidence even as broader industry peers navigate elevated medical cost pressures; the board also lifted its quarterly dividend to $1.56 per share, reinforcing Cigna's commitment to returning capital to shareholders.
Key Takeaways
- • Strong specialty pharmacy growth within Evernorth Health Services
- • Growth of existing client relationships and new business in Pharmacy Benefit Services
- • Increased adoption of biosimilars in Specialty and Care Services
- • Higher contributions from stop loss products in Cigna Healthcare Q4
- • Premium rate increases to cover expected increases in medical costs
- • SG&A expense ratio improvement from business mix shift
- • Onboarding of a new government contract driving 18% growth in behavioral care customers
CI YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
CI Revenue by Segment
With YoY comparisons, source: SEC Filings
“In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients.”
— David M. Cordani, Q4 2025 Earnings Press Release
CI Earnings Trends
CI vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CI EPS Trend
Earnings per share: estimate vs actual
CI Revenue Trend
Quarterly revenue: estimate vs actual
CI Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $7.79 | — | $68.49B | — |
| Q4 25 BEAT FY | $7.65 | $8.08 | +5.65% | $72.47B | +9.17% |
| FY Full Year | — | $29.84 | — | $274.90B | — |
| Q3 25 BEAT | $7.64 | $7.83 | +2.47% | $69.75B | +4.50% |
| Q2 25 BEAT | $7.15 | $7.20 | +0.65% | $67.18B | +7.30% |
| Q1 25 BEAT | $6.35 | $6.74 | +6.17% | $65.50B | +8.48% |